InvestorsHub Logo
Followers 898
Posts 149052
Boards Moderated 0
Alias Born 08/13/2010

Re: BottomBounce post# 479465

Friday, 07/13/2018 10:12:58 AM

Friday, July 13, 2018 10:12:58 AM

Post# of 618858
$INSY Unwavering Commitment to R&D as Company’s Driving Force

INSYS has invested approximately $250 million in research and development (R&D) since 2014, including nearly $140 million in 2016 and 2017.
Our company has advanced a new R&D vision, commencing a shift of resources from opioids to a clear, internal focus on cannabinoids, including clinical trials in infantile spasms (Phase 3), childhood absence epilepsy (Phase 2) and Prader-Willi syndrome (Phase 2), as well as the collaboration in autism research with UC San Diego’s Center for Medicinal Cannabis Research. Additional research partnerships under consideration include addiction, childhood schizophrenia/early psychosis and post-traumatic stress disorder (PTSD).
Consistent with our mission to serve the interests of patients in need of innovative therapies, our company has prioritized research programs of two life-saving investigational products (naloxone and epinephrine) as part of fulfilling our commitment to be a socially-responsible, healthcare community citizen.
Initial clinical trials of these two product candidates—naloxone nasal spray for opioid overdose and epinephrine nasal spray for anaphylaxis—showed promising results, thereby providing hope for our company to file NDAs for these two life-saving potential products in 2018 and 2019, respectively.
Filing these two NDAs would support our company’s aspirational goal of filing at least one NDA per year over the next five years.

Our company continues to put behind it the significant challenges caused by the inappropriate actions of certain former employees, most of which is over four or more years ago. It is our hope that our actions can help us continue regaining the trust of the healthcare community as we focus on the matters we can control. We believe that we have established a strong foundation to accomplish our stated mission and to bring value to patients and other stakeholders we have the privilege to serve.

Nothing I say, post, or do should ever be considered financial advice. I may be holding a long, short or no position. I am NOT or NEVER have I been compensated to post on here or anywhere and all my posts are for entertainment purposes only.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.